US 12,111,323 B2
Classification of periodontitis patients
Supriyo Chatterjea, Eindhoven (NL); Marinus Karel Johannes De Jager, Eindhoven (NL); Amir Hussein Rmaile, Eindhoven (NL); Gerben Kooijman, Leende (NL); Michael Alex Van Hartskamp, Eindhoven (NL); Philip Preshaw, Newcastle upon Tyne (GB); and John J Taylor, Framlington Place (GB)
Assigned to KONINKLIJKE PHILIPS N.V., Eindhoven (NL)
Appl. No. 16/758,902
Filed by KONINKLIJKE PHILIPS N.V., Eindhoven (NL)
PCT Filed Oct. 18, 2018, PCT No. PCT/EP2018/078486
§ 371(c)(1), (2) Date Apr. 24, 2020,
PCT Pub. No. WO2019/086252, PCT Pub. Date May 9, 2019.
Claims priority of application No. 17199175 (EP), filed on Oct. 30, 2017.
Prior Publication US 2021/0181209 A1, Jun. 17, 2021
Int. Cl. G01N 33/68 (2006.01)
CPC G01N 33/6893 (2013.01) [G01N 2333/4753 (2013.01); G01N 2333/5412 (2013.01); G01N 2333/545 (2013.01); G01N 2333/78 (2013.01); G01N 2333/8146 (2013.01); G01N 2333/96494 (2013.01); G01N 2800/18 (2013.01)] 17 Claims
 
1. A system for classifying a human subject as having mild periodontitis or advanced periodontitis, the system comprising:
at least one detector configured to measure concentrations of biomarkers in a sample of oral fluid of the subject, the biomarkers including Hepatocyte Growth Factor (HGF), Matrix metalloproteinase 8 (MMP8), Matrix metalloproteinase 9 (MMP9), Interleukin-1β (IL1β), Interleukin-6 (IL6), and Collagen Telopeptide; and
one or more processors configured to interface with the at least one detector to receive the measured concentrations of the biomarkers in the sample of oral fluid of the subject;
wherein, in a first stage, the at least one detector is configured to measure first-stage concentrations of a first set of biomarkers comprising HGF, MMP8, and MMP9 to obtain a first measurement result of the first-stage concentrations,
wherein the one or more processors are configured to process the first-stage concentrations to determine whether to measure, in a second stage, second-stage concentrations of a second set of biomarkers comprising IL1-β, IL6, and Collagen Telopeptide,
wherein the at least one detector is configured to obtain a second measurement result of the second-stage concentrations when the one or more processors determine to measure the second-stage concentrations, and
wherein the one or more processors are configured to process the second-stage concentrations to determine a classification result including an indication of mild periodontitis or advanced periodontitis, the classification result enabling determination of a treatment of the subject.